Mediar Therapeutics (Cambridge, MA, USA), a company developing a portfolio of first-in-class therapies to treat fibrosis, announces a US$105m financing including a US$85m Series A co-led by Novartis Venture Fund and Sofinnova Partners (France). The round is further joined by Pfizer Ventures, Mission BioCapital, Bristol-Myers Squibb, Eli Lilly, Ono Venture Investment, Mass General Brigham Ventures but also from more European VCs like by Gimv together with Pureos.
Danish Teitur Trophics ApS announced the completion of a €28m Series A funding to progress drugs against several neurodegenerative diseases.
Pfizer strengthens its oncology portfolio by acquiring Seagen, the biotech specialist in antibody-drug conjugates technology.
Paris-based AI-inspired drug discovery specialist Iktos SA has closed a €15.5m financing to expand its platform and kick-start the new CRO Iktos Robotics.
The charity Cancer Research UK and UCB SA collaborate on the development of two potential cures for cancer.
Noema Pharma AG receives €104m in oversubscribed Series B financing round to advance its central nervous system pipeline.
The eye disease specialist Oculis Holding AG has been listed on Nasdaq following the merger of Oculis SA with European Biotech Acquisition Corp.
Antiverse Ltd.’s AI identified eight antibodies with therapeutic potential for humans and raised €2.8m in funding for continued in-house development.
Drug developer Confo Therapeutics and Eli Lilly & Company have inked a worldwide licensing agreement to co develop Confo’s neurophatic pain candidate CFTX-1554.
The fourth fund of High-Tech Gründerfonds has reached a final fund volume of €493.8m